Octopus Biosafety (STU:OCR) Change In Receivables: €0.00 Mil (TTM As of Dec. 2024)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

STU:OCR Octopus Biosafety STU:OCR
7 GF Score
Price €0.15
GF Value €0.08
! 2 Warning Signs
View Full Analysis

What is Octopus Biosafety Change In Receivables?

Octopus Biosafety STU:OCR 7 Change In Receivables is €0.00 Mil as of Dec. 2024. GuruFocus rates STU:OCR with a GF Score™ of 7/100 and a GF Value™ of €0.08. The stock has 2 warning signs investors should review.

Octopus Biosafety's change in receivables for the quarter that ended in Dec. 2024 was €0.00 Mil. It means Octopus Biosafety's Accounts Receivable stayed the same from Dec. 2023 to Dec. 2024 .

Octopus Biosafety's change in receivables for the fiscal year that ended in Dec. 2024 was €0.00 Mil. It means Octopus Biosafety's Accounts Receivable stayed the same from Dec. 2023 to Dec. 2024 .

Octopus Biosafety's Accounts Receivable for the quarter that ended in Dec. 2024 was €0.03 Mil.

Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed. Octopus Biosafety's Days Sales Outstanding for the six months ended in Dec. 2024 was 87.74.

In Ben Graham's calculation of liquidation value, Apple Inc's Accounts Receivable are only considered to be worth 75% of book value. Octopus Biosafety's liquidation value for the six months ended in Dec. 2024 was €-1.10 Mil.

Octopus Biosafety  (STU:OCR) Change In Receivables Explanation

1. Accounts Receivable are created when a customer has received a product but has not yet paid for that product. Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.

Octopus Biosafety's Days Sales Outstanding for the quarter that ended in Dec. 2024 is calculated as:

Days Sales Outstanding
=Accounts Receivable/Revenue*Days in Period
=0.025/0.052*91
=87.74

2. In Ben Graham's calculation of liquidation value, Octopus Biosafety's accounts receivable are only considered to be worth 75% of book value:

Octopus Biosafety's liquidation value for the quarter that ended in Dec. 2024 is calculated as:

Liquidation Value
=Cash, Cash Equivalents, Marketable Securities-Total Liabilities+(0.75 * Accounts Receivable)+(0.5 * Total Inventories)
=0.023-1.145+0.75 * 0.025+0.5 * 0
=-1.10

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Octopus Biosafety Change In Receivables Related Terms

Octopus Biosafety Change In Receivables Historical Data

* Premium members only.

The historical data trend for Octopus Biosafety's Change In Receivables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Octopus Biosafety Change In Receivables Chart

Octopus Biosafety Annual Data
Trend Jun14 Jun15 Jun16 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Change In Receivables
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

Octopus Biosafety Semi-Annual Data
Jun14 Jun15 Jun16 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Change In Receivables Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
STU:OCR
7GF Score
Octopus Biosafety STU:OCR
Change In Receivables is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Octopus Biosafety Change In Receivables Calculation

Change In Accounts Receivable relative to the previous period. It is any increase or decrease in the cash a company is owed by its customers.

For stock reported annually, GuruFocus uses latest annual data as the TTM data. Change In Receivables for the trailing twelve months (TTM) ended in Dec. 2024 was €0.00 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Change In Receivables →
What does a Change In Receivables of €0.00 Mil mean?
Octopus Biosafety (STU:OCR) has a Change In Receivables of €0.00 Mil as of Dec. 2024. Change in Receivables is the difference between current-period receivables and past-period receivables. View historical data for Octopus Biosafety and its competitors.
Is Octopus Biosafety's Change In Receivables too high?
Octopus Biosafety's current Change In Receivables is €0.00 Mil. Overall, Octopus Biosafety has a GF Score™ of 7/100, reflecting its overall financial health beyond just this single metric.
How does Octopus Biosafety's Change In Receivables compare to DELL and ANET?
Octopus Biosafety's Change In Receivables of €0.00 Mil can be compared against companies in the Hardware industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Change In Receivables for a Hardware company?
A good Change In Receivables depends on the Hardware industry context. However, Change In Receivables should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Change In Receivables mean?
A high Change In Receivables can signal that a stock is expensive relative to its fundamentals. Change in Receivables is the difference between current-period receivables and past-period receivables. View historical data for Octopus Biosafety and its competitors. Octopus Biosafety's current Change In Receivables is €0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Octopus Biosafety stock overvalued right now?
Octopus Biosafety (STU:OCR) has a current Change In Receivables of €0.00 Mil. The stock's GF Value™ is €0.08, compared to a current price of €0.15 — trading 83.8% above its estimated fair value. The current Change In Receivables is €0.00 Mil. Octopus Biosafety's overall GF Score™ is 7/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Change In Receivables calculated?
Change In Receivables is calculated from a company's financial statements. For Octopus Biosafety (STU:OCR), the current Change In Receivables is €0.00 Mil as of Dec. 2024. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Octopus Biosafety (STU:OCR) Overvalued in 2026?

Based on GuruFocus' analysis, Octopus Biosafety stock appears to be overvalued. The current stock price of €0.15 is trading 83.8% above its estimated GF Value™ of €0.08.

Key valuation signals for STU:OCR:

  • Change In Receivables: €0.00 Mil
  • GF Value™: €0.08 vs. price of €0.15 (83.8% above fair value)
  • GF Score™: 7/100 with 2 warning signs

No single metric tells the full story. See the STU:OCR stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Octopus Biosafety Business Description

Other Exchanges MLOCT:France
Address 29 rue Saint Pierre, Cholet, FRA, 49300
Octopus Biosafety is engaged in the design, manufacture and marketing of mobile, autonomous, intelligent and modular robots for use in Agro-food sector, Healthcare sector, Defense sector, Civil Protection sector, and Surveillance and Transport sector.
7GF Score

Get the complete analysis for STU:OCR

Change In Receivables is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€0.15
Price
€0.08
GF Value